PPAR alpha activators, pharmaceutical compositions containing such
compounds and the use of such compounds to elevate certain plasma lipid
levels, including high density lipoprotein-cholesterol and to lower
certain other plasma lipid levels, such as LDL-cholesterol and
triglycerides and accordingly to treat diseases which are exacerbated by
low levels of HDL cholesterol and/or high levels of LDL-cholesterol and
triglycerides, such as atherosclerosis and cardiovascular diseases, in
mammals, including humans.
